IMpella-Protected CArdiaC Surgery Trial (IMPACT)

Abiomed

Status

Invitation-only

Conditions

Left Ventricular Dysfunction

Treatments

Device: Impella 5.5 with SmartAssist

Study type

Interventional

Funder types

Industry

Identifiers

NCT05529654

VV-TMF-20447

Details and patient eligibility

About

The purpose of this Trial is to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients, with the overall aim to evaluate if using Impella 5.5 with SmartAssist (Impella 5.5) peri-operatively improves early hemodynamics, end-organ function and clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.

Full description

This is a prospective single-armed Trial to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients. A concurrent Registry will also be performed to collect information on patients meeting Exclusion Criteria and those not approached for enrollment. The overall aim is to evaluate if using Impella 5.5 peri-operatively improves early hemodynamics, end-organ function and subsequent clinical outcomes in patients with severely reduced LV function undergoing cardiac surgery.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Hemodynamically stable patients undergoing one of the following cardiac surgery procedures on CPB including aortic cross-clamping and cardioplegic arrest:
- Isolated CABG
- Isolated mitral valve repair or mitral valve replacement (MVR)
- Isolated biological aortic valve replacement (AVR)
- At least two of the following: CABG, MVR, AVR, or tricuspid valve repair or replacement (TVR)
- Additional concomitant procedures permitted:
  1. Atrial septal defect (ASD) or patent foramen ovale (PFO) repair or closure
  2. Atrial fibrillation ablation procedures
  3. Left atrial ablation (all forms including complete left/right side Cox Maze)
  4. Coronary endarterectomy
LVEF within 30 days before surgery of either:
- ≤25% measured by echocardiogram or cardiac MRI, OR
- LVEF ≤35%, measured as above, for patients with significant mitral regurgitation (MR 3+ or 4+) and planned corrective mitral valve surgery (including MV replacement or repair)
  - Any subject with EF <20% must have viability assessment performed to assess CABG candidacy (MRI preferred)
Age 18 years or older
Subject (or subject's LAR, if allowed by IRB) has signed Informed Consent Form

Exclusion criteria

Salvage operation (cardiac arrest within 24 hours prior to index surgery)
Unresponsive state within 24 hours of the time of surgery
Any inotrope within 72 hours of surgery
Any MCS device (such as IABP, ECMO, Impella®, CentriMag™ or TandemHeart®) in place at time of informed consent and less than 24 hours prior to index study procedure
RV dysfunction requiring mechanical or inotropic support pre-operatively and/or likely to be needed post-operatively
Index procedures requiring total circulatory arrest (TCA), such as aortic arch replacement, planned durable LVAD, durable RVAD, planned right-sided temporary mechanical support of any kind, total artificial heart (TAH), cardiac transplantation, pericardiectomy, pulmonary thromboendarterectomy and septal myectomy
Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade or other conditions in which cardiac output is dependent on venous return
Ventricular septal defect (VSD)
Stroke within 30 days of the index cardiac surgical procedure
Prior mantle field chest irradiation
Prior solid organ or hematologic transplantation (heart, kidney, liver, lung, pancreas, bone marrow) or durable LVAD
History of chronic dialysis
Pre-existing liver dysfunction defined as: Child-Pugh Class B or C
Pre-existing pulmonary disease requiring home oxygen or "severe pulmonary disease" determined by enrolling Investigator
Systemic active infection or evidence of systemic bacterial, fungal or viral infection within 72 hours before surgery (blood culture positive with leukocytosis)
Confirmed COVID-19 infection within two weeks prior to operation
Suspected or known pregnancy
Participation in the active treatment or follow-up phase of another interventional clinical trial of an investigational drug or device which has not reached its primary endpoint
Known contraindication to heparin; History of bleeding diathesis or known coagulopathy or will refuse blood transfusions
Inability to perform aortic cross-clamp, such as due to porcelain aorta
Any contraindication or inability to place Impella 5.5 (per the IFU), including LV thrombus and/or presence of a mechanical aortic valve
Any organ condition, concomitant disease (e.g., psychiatric illness, current severe alcoholism or current drug abuse, cancer, hepatic or kidney disease), with life expectancy of ≤2 years or other abnormality that itself or the treatment of which could interfere with the conduct of the trial or that, in the opinion of the investigator and/or Sponsor's medical monitor, would pose an unacceptable risk to the patient in the trial.
Patient has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with trial procedures
Patient belongs to a vulnerable population [Vulnerable patient populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention]